Mechanism of Action Paroxetine is a potent and selective 5-hydroxytryptamine reuptake inhibitor (5-HT, serotonin). It is believed that its antidepressant activity and effectiveness in the treatment of obsessive-compulsive (OCD) and panic disorder is due to the specific inhibition of serotonin reuptake in brain neurons. Buy Paroxetine film-coated tablets over the counter In its chemical structure, paroxetine differs from tricyclic, tetracyclic and other known antidepressants. Paroxetine has a weak affinity for muscarinic cholinergic receptors, and animal studies have shown that it has only weak anticholinergic properties. In accordance with the selective action of paroxetine, in vitro studies have shown that, unlike tricyclic antidepressants, it has a weak affinity for α1, α2 and β-adrenergic receptors, as well as dopamine (D2), 5-HT1-like, 5HT2 - and histamine (H1) receptors. This lack of interaction with postsynaptic receptors in vitro is confirmed by in vivo studies that have shown that paroxetine has no ability to inhibit the central nervous system (CNS) and cause arterial hypotension. Pharmacodynamic effects Paroxetine does not violate psychomotor functions and does not enhance the inhibitory effect of ethanol on the central nervous system. Like other selective serotonin reuptake inhibitors, paroxetine causes symptoms of over-stimulation of 5-HT receptors when administered to animals that previously received monoamine oxidase inhibitors (MAOs) or tryptophan. Studies of the behavior and changes in EEG have demonstrated that paroxetine induces weak activating effects at doses higher than those required to inhibit serotonin reuptake. By its nature, its activating properties are not “amphetamine-like”. Animal studies have shown that paroxetine does not affect the cardiovascular system. In healthy individuals, paroxetine does not cause clinically significant changes in blood pressure, heart rate, or ECG. Studies have shown that, unlike antidepressants that inhibit the reuptake of norepinephrine, paroxetine has a much lower ability to inhibit the antihypertensive effects of guanethidine.
Danger or not?
As can be seen from the reviews of people, "Paroxetine", although it causes side effects on the period of treatment, does not affect the body in the long term. When you stop using the drug, the negative effects go away by themselves. Many of the side effects accompany only the beginning of therapy..
As follows from the instructions for use, tablets "Paroxetine" affect the central and peripheral 5-HT3 receptors. Experts suggest that this is what leads to negative reactions from the gastrointestinal tract.
This remedy really provokes side effects, but it is much easier to eliminate them than similar reactions of the body caused by taking other medications from the same group of antidepressants.
Reviews of "Paroxetine" show that many patients gained weight or experienced impotence while taking the drug, but the main problem was nevertheless eliminated.
• Hypersensitivity to paroxetine and any other component that is part of the drug; • Paroxetine is contraindicated in combination with monoamine oxidase inhibitors (MAOI). http://www.healthline.com/health/paroxetine-oral-tablet In exceptional cases, linezolid (an antibiotic that is a reversible nonselective MAOI) can be combined with paroxetine, provided that acceptable alternatives to linezolid treatment are unavailable, and the potential benefits of using linezolid exceed the risks of serotonin syndrome or malignant antipsychotic syndrome, as a reaction in a particular patient. Equipment to closely monitor the symptoms of serotonin syndrome and monitor blood pressure should be available. Paroxetine treatment is allowed: - 2 weeks after stopping treatment with irreversible MAOIs or - at least 24 hours after stopping treatment with reversible MAOIs (for example, moclobemide, linezolid, methylthioninium chloride (methylene blue)), - at least , 1 week between the abolition of paroxetine and the start of therapy with any MAOI; • combined use with thioridazine. Paroxetine should not be used in combination with thioridazine, since, like other drugs that inhibit the activity of the hepatic isoenzyme CYP2D6, paroxetine can increase plasma thioridazine concentrations, which can lead to a prolongation of the QTc interval and associated ventricular pirouette type arrhythmia, which is potentially threatening life, and sudden death; • combined use with pimozide; • use in children and adolescents under 18 years of age. Controlled clinical studies of paroxetine in the treatment of depression in children and adolescents have not proved its effectiveness, therefore, the drug is not indicated for the treatment of this age group. The safety and effectiveness of paroxetine have not been studied when used in patients of a younger age category (under 7 years).